Apolipoprotein E and Apolipoprotein E Receptors: Normal Biology and Roles in Alzheimer Disease
Open accessThe DOI matches its Crossref record; 224 of the 227 references it cites were found in a registry or an index.
Abstract
Apolipoprotein E (APOE) genotype is the major genetic risk factor for Alzheimer disease (AD); the 14 allele increases risk and the 12 allele is protective.In the central nervous system (CNS), apoE is produced by glial cells, is present in high-density-like lipoproteins, interacts with several receptors that are members of the low-density lipoprotein receptor (LDLR) family, and is a protein that binds to the amyloid-b (Ab) peptide.There are a variety of mechanisms by which apoE isoform may influence risk for AD.There is substantial evidence that differential effects of apoE isoform on AD risk are influenced by the ability of apoE to affect Ab aggregation and clearance in the brain.Other mechanisms are also likely to play a role in the ability of apoE to influence CNS function as well as AD, including effects on synaptic plasticity, cell signaling, lipid transport and metabolism, and neuroinflammation.ApoE receptors, including LDLRs, Apoer2, very low-density lipoprotein receptors (VLDLRs), and lipoprotein receptor-related protein 1 (LRP1) appear to influence both the CNS effects of apoE as well as Ab metabolism and toxicity.Therapeutic strategies based on apoE and apoE receptors may include influencing apoE/Ab interactions, apoE structure, apoE lipidation, LDLR receptor family member function, and signaling.Understanding the normal and disease-related biology connecting apoE, apoE receptors, and AD is likely to provide novel insights into AD pathogenesis and treatment.A lzheimer disease (AD), specifically the late- onset form of AD (LOAD), is the most common cause of dementia in individuals older than 60 years of age.Although mutations in the genes PS1, PS2, and APP cause less common forms of early-onset, autosomal dominant familial AD (FAD), these cases represent ,1% of AD.In addition to the genes that cause FAD, LOAD also has a strong genetic component.Although several susceptibility genes for AD have been reported, by far the strongest genetic risk factor for LOAD is apolipoprotein
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Those who inherit one copy of the e4 form have about three times the risk of developing Alzheimer's compared with those with two copies of the e3 form, while those who inherit two copies of the e4 form have an estimated eight-to 12-fold risk.[73][74][75]”
From 2023 Alzheimer's disease facts and figures (2023) · cites this paper as [74]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, LDLR and LRP1 disruption by PCSK9 may be crucial for AD progression since they are the major ApoE receptors in the brain, are involved in lipid homeostasis and intracellular signaling, and are fundamental for the regulation of neuronal structure and synaptogenesis [79].”
From The Emerging Role of PCSK9 in the Pathogenesis of Alzheimer’s Disease: A Possible Target for the Disease Treatment (2024) · cites this paper as [79]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ApoE isoforms may differentially regulate brain lipid metabolism in AD and primary tauopathies.1”
From Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegeneration with an LXR agonist (2024) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A single copy of the ε4 allele increases disease risk by approximately four-fold while two copies of the allele increase disease risk by approximately twelvefold relative to individuals who are ε3/ε3 [1, 4, 5].”
From ApoE lipoproteins in the central nervous system under homeostasis and role in Alzheimer’s disease and related disorders (2026) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the brain most cholesterol is produced de novo by astrocytes, and then transported to neurons and other cells by combining with ApoE, mainly synthesized by astrocytes, to form lipoproteins that are secreted through the ATP-binding cassette (ABC) transporters [9,10].”
From ApoE3 vs. ApoE4 Astrocytes: A Detailed Analysis Provides New Insights into Differences in Cholesterol Homeostasis (2022) · cites this paper as [9]
Experimental — accuracy not yet measured
18 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769 · cited 1×
“…and several mechanisms have been proposed to explain this effect (Lambert et al. 1998; Walsh et al. 2002; Lacor et al. 2004; Snyder et al. 2005; Lesne et al. 2006; Townsend et al. 2006; Haass and Selkoe 2007; Shankar et al. 2007; Berman et al. 2008; Puzzo et al. 2008; Shankar et al. 2008;…”
BackgroundRetractedCorder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429 · cited 3×
“…Cite this article as Cold Spring Harb Perspect Med 2012;2:a006312 1 w w w .p er sp ec ti ve si n m ed ic in e. o rg E (APOE) genotype, with the 14 allele being an AD risk factor and the 12 allele being protective relative to the prevalent 13 allele (Corder et al. 1993; Strittmatter et al. 1993a).”
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744 · cited 1×
“…to explain this effect (Lambert et al. 1998; Walsh et al. 2002; Lacor et al. 2004; Snyder et al. 2005; Lesne et al. 2006; Townsend et al. 2006; Haass and Selkoe 2007; Shankar et al. 2007; Berman et al. 2008; Puzzo et al. 2008; Shankar et al. 2008; Nygaard and Strittmatter 2009; Gimbel et al.…”
BackgroundWalsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291 · cited 1×
“…oligomers are strong inducers of synaptic suppression, and several mechanisms have been proposed to explain this effect (Lambert et al. 1998; Walsh et al. 2002; Lacor et al. 2004; Snyder et al. 2005; Lesne et al. 2006; Townsend et al. 2006; Haass and Selkoe 2007; Shankar et al. 2007; Berman…”
BackgroundStrittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268 · cited 4×
“…Cite this article as Cold Spring Harb Perspect Med 2012;2:a006312 1 w w w .p er sp ec ti ve si n m ed ic in e. o rg E (APOE) genotype, with the 14 allele being an AD risk factor and the 12 allele being protective relative to the prevalent 13 allele (Corder et al. 1993; Strittmatter et al. 1993a).”
BackgroundInfluentialApolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028 · cited 17×
“In contrast, apoAI in CNS is derived from the periphery (SorciThomas et al. 1988).”
BackgroundInfluentialShankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685 · cited 1×
“…Snyder et al. 2005; Lesne et al. 2006; Townsend et al. 2006; Haass and Selkoe 2007; Shankar et al. 2007; Berman et al. 2008; Puzzo et al. 2008; Shankar et al. 2008; Nygaard and Strittmatter 2009; Gimbel et al. 2010; Palop and Mucke 2010; Renner et al. 2010; Ronicke et al. 2010) (see Mucke and…”
BackgroundDiffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506 · cited 2×
“Ab1-42 oligomers are strong inducers of synaptic suppression, and several mechanisms have been proposed to explain this effect (Lambert et al. 1998; Walsh et al. 2002; Lacor et al. 2004; Snyder et al. 2005; Lesne et al. 2006; Townsend et al. 2006; Haass and Selkoe 2007; Shankar et al. 2007; Berman et al. 2008; Puzzo e…”
BackgroundHarold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326 · cited 1×
“Interestingly, single-nucleotide polymorphisms in clusterin have been shown to be a risk factor for AD (Harold et al. 2009; Lambert et al. 2009).”
BackgroundThe Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280 · cited 1×
“1) (Zlokovic 2008).”
Research works printed but not linked: 1
- Sanan DA, Weisgraber KH, Russel SJ, Mahley RW, Huang D, Saunders A, Schmechel D, Wisniewksi T, Frangione B, Roses B, et al. 1994. Apolipoprotein E associates with b amyloid peptide of Alzheimer's disease to form novel monofibrils. J Clin Invest 94: 860 -869.
Cited by
Items 601–700 of 810
Yoon, S., & Kim, Y. (2015) · Global Medical Genetics · doi:10.3934/genet.2015.3.230 · Cited by 5
“Specifically, ApoE plays a role in mediating cell signaling, synaptic plasticity, and neuroinflammation as well as in cholesterol and lipid transport [15].”
Cerebrospinal Fluid Biomarkers in Alzheimer’s Disease
Zetterberg, H., & Schott, J. M. (2016) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-3560-4_11 · Cited by 5
Badrnya, S., Doherty, T., Richardson, C., McConnell, R. I., Lamont, J. V., Veitinger, M., Fitzgerald, S. P., Zellner, M., & Umlauf, E. (2017) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2017-0618 · Cited by 5
“Furthermore, APOE4 was linked to a reduction of gray matter in young to middle-aged cognitively healthy adults, an age at which AD is not yet apparent [5, 15, 19].”
BackgroundHildre, A. S., Solvang, S.-E. H., Aarsland, D., Midttun, Ø., McCann, A., Ervik, A. O., Nygard, O. K., Ueland, P. M., Nordrehaug, J. E., & Giil, L. M. (2019) · Brain Research · doi:10.1016/j.brainres.2019.146519 · Cited by 5
Mika, M., Wikiera, A., Antończyk, A., & Grabacka, M. (2020) · International Journal of Food Sciences and Nutrition · doi:10.1080/09637486.2020.1817345 · Cited by 5
“Apolipoprotein E (apoE) is the main protein component present on the surface of various lipoproteins and serves as a ligand for the receptors that are responsible for lipoprotein uptake: LDL receptor (LDLr), LDL receptor-related protein (LRP), VLDL receptor (VLDLr) (Holtzman et al. 2012).”
BackgroundBenedusi, V. (2018) · Materials and Methods · doi:10.13070/mm.en.8.2665 · Cited by 6
Gouras, G. K. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.00159-8 · Cited by 5
Lipids and Lipoproteins in Alzheimer’s Disease
Stukas, S. K., Kulić, I., Zareyan, S., & Wellington, C. L. (2015) · InTech eBooks · doi:10.5772/59808 · Cited by 6
“Of these, LDLR is the only receptor that has apoE as its only known ligand in the CNS [69].”
BackgroundThe Effects of Glycerophospholipids and Fatty Acids on APP Processing
Mett, J., Hartmann, T., & Grimm, M. O. W. (2016) · Elsevier eBooks · doi:10.1016/b978-1-63067-036-8.00013-5 · Cited by 6
Genetics of Alzheimer´S Disease
Campos‐Peña, V., Gmez, R., & Antônio, M. (2014) · InTech eBooks · doi:10.5772/58286 · Cited by 5
“Allele 4 of apolipoprotein E (ApoE4) has been reported to represent the main identified risk factor for sporadic AD [44, 49, 108].”
BackgroundKönig, T., Silvaieh, S., Parvizi, T., Wurm, R., Goeschl, S., Uhlik, E., Farr, C. V., Berger–Sieczkowski, E., Untersteiner, H., Zimprich, A. A., et al. (2025) · Genetics in Medicine · doi:10.1016/j.gim.2025.101517 · Cited by 4
Paudel, P., Sah, A., & Paudel, P. (2025) · Clinical Genetics · doi:10.1111/cge.70064 · Cited by 5
Paradise, V., Konrad, K. D., Nguyen, C., Sharif, N. A., Wang, X., Mukim, R. D., Sabu, M., Corjuc, B. T., Bafia, J., Fu, J. M., et al. (2026) · Nature Neuroscience · doi:10.1038/s41593-026-02297-x · Cited by 4
“Considering ApoE is primarily a glia-derived secreted extracellular factor 10 , we hypothesized that specialized proteostasis machinery at the neuronal plasma membrane might provide a critical link to intracellular tau stability.”
Self-citationALZHEIMER HASTALIĞI, RİSK FAKTÖRLERİ VE TEDAVİ
Yıldırım, N., & Eke, B. C. (2024) · Ankara Universitesi Eczacilik Fakultesi Dergisi · doi:10.33483/jfpau.1441827 · Cited by 4
“Bunun aksine, ApoE ε2 taşıyıcılarının, ApoE ε3 ve ApoE ε4 taşıyıcılarına göre ‘korunan’ bir durumda olduğu ve bu nedenle ApoE ε4 proteini 'toksik' gibi görünürken, ApoE ε2’nin AH'ye karşı 'koruyucu' olduğu yönünde görüşler bulunmaktadır [29,30].”
Zeng, F., Tiwari, S., Chok, A., Zhou, Y., Zhao, Y., Chen, X., Hao, Y., Zhu, K., Kettenmann, H., & Xiang, X. (2025) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.07.013 · Cited by 5
Wu, C., Ling, N., Vieu, P., & Fan, G. (2024) · Test · doi:10.1007/s11749-024-00946-6 · Cited by 4
“More research on APOE-(cid:25) 4 can be also found in the reviews by Holtzman et al. (2012) and Liu et al. (2013) as well as Yamazaki et al. (2019).”
CD33 and clusterin interact biophysically and genetically to modulate Alzheimer risk
Dodd, R. B., Enomoto, M., Zhou, Y., Satoh, K., Zhang, Y., Chen, F., Acheson, B., Ghaffari, D., Sayn-Wittgenstein, E., Manning, J. J., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-75140-3 · Cited by 6
Self-citationCalon, F. (2014) · Cahiers de Nutrition et de Diététique · doi:10.1016/j.cnd.2014.03.003 · Cited by 4
“Au contraire, l’allèle 2 de l’ApoE semblerait protéger de la maladie par rapport aux individus ApoE 3 [81].”
BackgroundLedo, A., Rocha, B. S., & Laranjinha, J. A. N. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-11488-6_10 · Cited by 5
Contributing Factors of Neurodegeneration in Alzheimer’s Disease
Tailor, B. A., Pilozzi, A. R., & Huang, X. (2019) · Codon Publications eBooks · doi:10.15586/alzheimersdisease.2019.ch5 · Cited by 6
“Additionally, its strong ties to neurovascular dysfunction further confirm its contribution in AD manifestation (56).”
BackgroundSmall Molecule Phenotypic Screen Identifies Novel Regulators of LDLR Expression
Krishnan, N., Chen, X., Donnelly‐Roberts, D. L., Mohler, E. G., Holtzman, D. M., & Gopalakrishnan, S. M. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00851 · Cited by 5
Self-citationThe Impact of Apolipoprotein E Allelic Variants on Alzheimer’s Disease
Serrano, E., Sanz, P. G., & Barrantes, F. J. (2021) · Springer eBooks · doi:10.1007/978-3-030-61721-9_29 · Cited by 5
Rao, W., Meng, X., Li, K., Zhang, Y., & Zhang, X. Y. (2021) · Annals of General Psychiatry · doi:10.1186/s12991-021-00376-w · Cited by 5
“Abbreviations ApoE: Apolipoprotein E; ApoA1: Apolipoprotein A1; ApoB: Apolipoprotein B; PANSS: Positive and Negative Syndrome Scale; GDP: Gross domestic product; GBD: Global burden of disease; YLD: Years of life lived with disability; BDNF: Brain-derived neurotrophic factor; ALFA: Allele Frequency Aggregator; LDL: Low…”
BackgroundBatawi, A. H. (2022) · International Journal of Neuroscience · doi:10.1080/00207454.2022.2082968 · Cited by 4
“…of the apolipoprotein e protein [10]. it was found that the ϵ 4 isoform facilitates the accumulation of aβ42 in senile plaques and disease onset [11]. additionally, clusterin (clu) gene is encoding a glycoprotein with many functions that are involved in several pathological and physiological…”
BackgroundWang, S., Ke, S., Liu, S., Wang, E., & Pan, T. (2023) · Neuroscience Letters · doi:10.1016/j.neulet.2023.137052 · Cited by 5
“Given the importance of APOE ε 4 to AD neuropathology [2,4,26], we hypothesized that the association of plasma p-tau181 with cognitive performance may vary by APOE 4 status.”
Recent Advancements in the Early Diagnosis and Treatment of Alzheimer's Disease
Wu, Y., Fu, L., Li, Q., Gao, X., Zhang, Y., Jin, C., Ding, F., Hong, S. C., Cai, H., & Li, Y. (2023) · Advanced Therapeutics · doi:10.1002/adtp.202300181 · Cited by 5
Farias, F., Benítez, B. A., & Cruchaga, C. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105247 · Cited by 6
“It has been hypothesized that APOE ’ s main effect on AD is through A β deposition as carriers of APOE ε 4 alleles show large amounts of brain A β deposition and low CSF A β 42 (Holtzman et al., 2012).”
Impact of APOE ε3 and ε4 genotypes on plasma proteome signatures in Alzheimer's diseasePreprint
Kaur, G., Poljak, A., Masters, C. L., Fowler, C. J., & Sachdev, P. S. (2022) · Research Square · doi:10.1101/2022.01.29.478291 · Cited by 4
“APOE ε4/ε3 carriers without AD are denoted as CNTLE4, 2.”
BackgroundMethodInfluentialA possible role of Apolipoprotein E in Idiopathic Generalized Epilepsy
Kabbage, M., Mrabet, S., Mounadi, M., Gharbi, A., Atrous, A., Abdelkefi, I., Gargouri, A., & Gouider, R. (2025) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2025.110554 · Cited by 3
Zhang, L., Zhang, L., Zhao, J., Zhang, W. Y., & Zhang, H. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05424-0 · Cited by 3
“This degradation-driven deficit may contribute to Aβ accumulation in AD, particularly given that VLDLR dysfunction disrupts neuronal lipid homeostasis and synergistic clearance mechanisms involving LRP1 or ApoER2 [49,50].”
Jiraanont, P., Wang, J. Y., Durbin-Johnson, B., Hwang, Y. H., Hessl, D. R., Rivera, S. M., Hagerman, R. J., & Tassone, F. (2026) · Neurobiology of Disease · doi:10.1016/j.nbd.2026.107292 · Cited by 3
“The neutral Apo ε 3 is the most common allele in all ethnic groups (Bertram and Tanzi, 2008; Vemuri et al., 2010; Holtzman et al., 2012; Liu et al., 2013; Reiman et al., 2020).”
Plasma Amyloid-β in Patients with Tangier Disease
Shahim, P., Bochem, A. E., Mattsson, N., Lautner, R., Blennow, K., Hovingh, G. K., Motazacker, M. M., & Zetterberg, H. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-122425 · Cited by 4
“The apolipoprotein E (APOE) 4 allele is strongly linked to AD but the exact molecular mechanisms underlying this well-replicated association are to date unknown [4, 10–12].”
Demographics and the Epidemiological Risk Factors for Dementia in Hispanic/Latino Populations
Fernández, L., & Johnson, N. J. (2020) · Springer eBooks · doi:10.1007/978-1-0716-0132-7_1 · Cited by 3
Mirheydari, M., Putta, P., Mann, E. K., & Kooijman, E. E. (2021) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.1c00271 · Cited by 3
Perspectives on the Role of APOE4 as a Therapeutic Target for Alzheimer’s Disease
Patel, K., Srivastava, S., Kushwah, S., & Mani, A. (2021) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-210027 · Cited by 4
Cai, Y., Fu, P., & Zhang, X. (2023) · Neuroscience Letters · doi:10.1016/j.neulet.2023.137161 · Cited by 3
The impact of disaster on cognition in geriatric population
Önder, Ö. (2024) · Health Sciences Quarterly · doi:10.26900/hsq.2243 · Cited by 3
“This association supports the increased negative effects of increased exposure to neurotoxins in dust on the development of Alzheimer’s disease with the contribution of increased blood-brain barrier permeability for APOE-ε4 carriers [27].”
BackgroundStefanini, E., Serrano‐Marín, J., Iglesias, A., Fernández, M. G., Sánchez-Navés, J., Alkozi, H. A., Bernal‐Casas, D., & Franco, R. (2025) · Exploration of Neuroprotective Therapy · doi:10.37349/ent.2025.100497 · Cited by 4
Apolipoprotein E isoforms and bone—of mice and men
Ralston, S. H. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1840 · Cited by 3
“APOE has also been implicated in the pathogenesis of Alzheimer’s disease, which is strongly associated with carriage of ApoE4; however, the mechanisms by which the ApoE4 variant predisposes to Alzheimer’s are incompletely understood.((2)) The experiments of Deickmann and colleagues((1)) were prompted by the observatio…”
BackgroundKimura, A., Hata, S., & Suzuki, T. (2015) · FEBS Letters · doi:10.1016/j.febslet.2015.07.017 · Cited by 3
Wu, Y., Srirajavatsavai, V., Monplaisir, K. M., Sambanthamurthi, R., & Gupta, S. V. (2015) · The FASEB Journal · doi:10.1096/fasebj.29.1_supplement.271.8 · Cited by 3
Wang, L., Pan, X., Fei, G., Wang, C., Wan, W., Sang, S., Wang, H., Wang, Z., & Zhong, C. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00071 · Cited by 4
APOE4 Regulates Synaptic Function by Directly Modulating the SNARE Complex AssemblyPreprint
Chen, F., Chen, Y., Chen, H., Wang, Y., Wei, W., Cai, Y., Liang, C., Cao, H., Chen, X., Ji, Y., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-380304/v1 · Cited by 3
ApoE expression across the CNS: Who, What, Where, When, and How (much)?
Nolt, G. L., Lucido, C. C., Smith, L. M., & Johnson, L. A. (2026) · Molecular Neurodegeneration Advances · doi:10.1186/s44477-026-00028-x · Cited by 2
“Through this central transport function, apoE supports numerous fundamental processes, including membrane repair, synaptic remodeling, myelin maintenance, lipid debris clearance, lipid metabolism, immune signaling, and blood–brain barrier integrity [1, 8–13, 203, 204].”
Simple In Vivo Models of Alzheimer’s Disease
Caito, S. W., & Newell-Caito, J. L. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802810-0.00011-8 · Cited by 3
Difficulties in diagnosing atypical variants of Alzheimer’s disease
Tappakhov, A. A., Nikolaeva, T. Y., Popova, T. E., & Shnayder, N. A. (2021) · Russian neurological Journal · doi:10.30629/2658-7947-2021-26-5-16-23 · Cited by 2
Das, G., & Milner, T. E. (2024) · Frontiers in Photonics · doi:10.3389/fphot.2024.1389683 · Cited by 2
Khan, A., Zubair, S., & Ali, I. (2025) · Neural Computing and Applications · doi:10.1007/s00521-025-11021-y · Cited by 2
“Risk factors for AD that cannot be altered include female gender, black race, Hispanic ethnicity, and genetic variables such as the apolipoprotein E gene [9–14].”
You, Y., Ward, J., Ho, F. K. W., Lyall, D. M., & Hastie, C. E. (2025) · Brain Communications · doi:10.1093/braincomms/fcaf350 · Cited by 2
Koo, B. G., Seo, H., Yun, Y., Kim, D., Kang, J. M., Cho, J., Lee, S.-Y., Lee, Y. J., Park, K. H., Lee, M. J., et al. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-026-01994-w · Cited by 2
“APOE, pres-ent in lipoprotein particles in the human brain, plays critical roles in amyloid precursor protein processing, Aβ clearance, and tau phosphorylation [14].”
Yuan, N. Y., Richards, W. D., Parham, K. T., Clark, S. G., & Lebakken, C. S. (2026) · Cells · doi:10.3390/cells15141266 · Cited by 2
“It has been found that ApoE aggregation in microglia leads to seeding of amyloid beta [103] and that ApoE4 increases A β [104] and tau [38] pathology relative to other ApoE isoforms.”
Peripheral markers of TBI and blood−brain barrier disruption
Washington, J., Murcko, R. M., & Janigro, D. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816346-7.00004-x · Cited by 2
Khan, J., & Tatlı, I. İ. (2023) · Springer eBooks · doi:10.1007/978-981-99-3848-3_8 · Cited by 3
Higher level of [3H]UCB-J binding in ApoE Ɛ4 allele carriers with Alzheimer disease
Mikkelsen, J. D., Linde-Atkins, P., & Pazarlar, B. A. (2025) · Neuroscience Letters · doi:10.1016/j.neulet.2025.138135 · Cited by 2
Lin, G., Liang, W., He, Q., Wang, Y., & Yang, X. (2025) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2025.117365 · Cited by 2
Transgenesis in Drug Discovery: Enhancing Target Identification and Validation
Mete, R., Das, S., Saha, A., Roy, S., Mondal, S., Bose, A., Basu, B., Elossaily, G. M., & Prajapati, B. G. (2025) · Molecular Biotechnology · doi:10.1007/s12033-025-01426-4 · Cited by 2
Identification of TMED10 as A Regulator for Neuronal Exocytosis of Amyloid Beta 42
Meng, P., Sha, L., Yu, X., Wang, Y., Zhang, E., Meng, K., Li, B., Zhao, Q., & Xu, Q. (2025) · Neuroscience Bulletin · doi:10.1007/s12264-025-01492-3 · Cited by 2
“However, we speculate that the former is more likely, as it has been shown that the entry of Aβ into neurons may lead to toxic accumulation [42, 43], while internalization by microglia [44], endothelial cells, or astroglia [45] appears to be a more likely pathway for Aβ uptake and degradation [46].”
Chen, X., Liang, H., & Geiger, J. D. (2014) · PubMed · Cited by 4
THE INFLUENCE OF DEMENTIA CAREGIVER MENTAL HEALTH ON QUALITY OF CARE IN ARGENTINA
Paredes, A. M. (2014) · VCU Scholars Compass (Virginia Commonwealth University) · doi:10.25772/6027-te62 · Cited by 3
Mediation Analysis in Understanding Mechanism of Alzheimer’s Disease Risk
Sajeev, G. (2015) · Digital Access to Scholarship at Harvard (DASH) (Harvard University) · Cited by 3
APOE genotype influences P3b amplitude and response to smoking abstinence in young adults
Coppens, R. P., Rabinovich, N. E., Kanneganti, R., Diggs, H. A., Wiggs, K. A., Healey, T. L., Huggenvik, J. I., Rose, G. M., & Gilbert, D. G. (2021) · Psychopharmacology · doi:10.1007/s00213-021-05763-5 · Cited by 1
Isaiah, A. (2025) · The Laryngoscope · doi:10.1002/lary.32235 · Cited by 1
Mahley, R. W. (2025) · Springer eBooks · doi:10.1007/978-3-031-52641-1_2-1 · Cited by 2
Yin, H., Li, X., Yang, J., Lü, J., Xu, Z., Bai, L., Liu, J., Sun, C., & Li, H. (2025) · Experimental Neurology · doi:10.1016/j.expneurol.2025.115539 · Cited by 1
Structural Analysis of Missense Mutations on the Stability of APOE3 and APOE4
Anthony, M., Xie, Y., O’Neil, J. N., & Teng, S. (2025) · Genes · doi:10.3390/genes16121509 · Cited by 2
Sharma, S., Rawat, E., Sharma, P., & Kapoor, D. U. (2026) · Discover Neuroscience · doi:10.1186/s13064-026-00231-2 · Cited by 1
Datta, D., Wang, M., & Arnsten, A. F. T. (2026) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2026.1750092 · Cited by 1
Akhter, N., Ho, N. A., Nangreave, R. C., Ahmad, S., Ducruet, A. F., & Bhatia, K. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1737073 · Cited by 1
“Given the established role of APOE isoforms in AD pathogenesis (Kim et al., 2009; Holtzman et al., 2012), this overlap was long attributed to APOE-mediated modulation of cognition via comorbid AD pathology in PD (Irwin et al., 2017).”
Heterogeneous causal mediation analysis using Bayesian additive regression trees
Liu, C., Qin, X., Talisa, V. B., & Wang, J. (2026) · Biometrics · doi:10.1093/biomtc/ujag079 · Cited by 2
“4 promotes the accumulation of amyloid plaques and neurofibril-lary tangles, which subsequently result in cognitive decline ( Holtzman et al., 2012 ) .”
Zhang, N., Chen, W. H., & Wang, M. (2026) · Animal Models and Experimental Medicine · doi:10.1002/ame2.70262 · Cited by 1
“11 Whereas the APOE3 isoform promotes peripheral A β clearance via binding to the LRP1 receptor, the structurally unstable APOE4 isoform has a reduced affinity for A β , consequently diminishing its hepatic uptake.”
Lashkari, F. M., Meybodi, A. M., Mansouri, Z., Kalantari, H., Farahmand, K., & Vaziri, H. (2015) · Egyptian Journal of Medical Human Genetics · doi:10.1016/j.ejmhg.2015.11.003 · Cited by 1
Is Alzheimer's Associated Amyloid Beta an Innate Immune Protein
Kandel, R., White, M. R., Hseih, I.-N., & Hartshorn, K. L. (2016) · InTech eBooks · doi:10.5772/63021 · Cited by 1
“In addition, there is evidence that APOEε4 may be linked to inflammatory responses in the brain through interaction with receptors on microglia [13].”
BackgroundIs Detection of Preclinical Alzheimer’s Disease Possible?
Brawer, S. (2018) · The Science Journal of the Lander College of Arts and Sciences · Cited by 1
Mild Cognitive Impairment and Early Dementia
Damasceno, B. P. (2020) · Springer eBooks · doi:10.1007/978-3-030-57267-9_20 · Cited by 1
Association of Serum Magnesium Concentration with Alzheimer’s Disease
Uddin, M. K., Habib, M. A., Islam, M., Khan, M. R. K., Rahman, H. Z., Rizvi, A. N., Bhuiyan, M. M., Barman, K. K., Showkat, S., Hannan, M., et al. (2017) · Bangladesh Journal of Neuroscience · doi:10.3329/bjn.v33i2.57520 · Cited by 1
Role of Liver in Alzheimer’s Disease
(2020) · ARC Journal of Neuroscience · doi:10.20431/2456-057x.0403003 · Cited by 1
“It is reported that Aβ binds to ApoE and maybe chaperoned in transport with cholesterol from the brainas a means of toxin clearance [28].”
BackgroundBaboo, G. K., Prasad, R., Mahajan, P., & Baths, V. (2022) · Annals of Neurosciences · doi:10.1177/09727531221117633 · Cited by 1
Misra, A. K., Bhattacharjee, A., Mukherjee, J., Kumar, S., & Mohanty, B. (2022) · Asian Journal of Medical Sciences · doi:10.3126/ajms.v13i12.48716 · Cited by 1
“86 ng/ml Insufficient 9 (18) 3 (6) 7 (14) 5 (10) 24 (48) Sufficient 5 (10) 8 (16) 3 (6) 5 (10) 21 (42) Total 2 (4) 0 (0) 2 (4) 1 (2) 5 (10) Figure 1: Correlation between Vitamin D levels and body mass index.”
Cholesterol in the Central Nervous System in Health and Disease
Skowronek, R. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-41192-2_21 · Cited by 2
Altered RNA Metabolism in Neurodegenerative Disorders
Chimata, A. V., Deshpande, P., & Singh, A. (2024) · Springer eBooks · doi:10.1007/978-981-97-4288-2_9 · Cited by 1
Role of Impaired ABC Transporters in Alzheimer’s Disease
Haque, M., Rather, G. A., Siddiqui, E. M., Jahan, S., Khan, A., Makeen, H. A., Alexiou, A. T., & Ashraf, G. M. (2021) · Springer eBooks · doi:10.1007/978-981-16-4558-7_13 · Cited by 1
Further study of the rôle played by fluorine in the causation of disease.
Spira, L. (1952) · PubMed · Cited by 2
Asaro, A. (2019) · Refubium (Universitätsbibliothek der Freien Universität Berlin) · doi:10.17169/refubium-25744 · Cited by 1
Liao, J., Liu, X., Chen, G., Wang, Z., Gu, X., Wei, L., Yu, S. P., & Ye, K. (2022) · Research Square · doi:10.21203/rs.3.rs-1632486/v1 · Cited by 1
Gallo, C. M., Kistler, S. A., Natrakul, A., Labadorf, A. T., Beffert, U., & Ho, A. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.12.523804 · Cited by 1
“…secreted glycoprotein mainly secreted from glial cells that binds to lipoprotein receptors including APOE receptor 2 (APOER2) in neurons and mediates a number of important processes, including receptor endocytosis, signaling, and regulation of receptor processing (Bu, 2009; Holtzman et al., 2012).”
BackgroundShafi, V., & Siddiqui, I. (2024) · Research Square · doi:10.21203/rs.3.rs-4408464/v1 · Cited by 1
Lam, S. (2021) · theses.fr (ABES) · doi:10.70675/60b353ffz56fcz41a2z9e53zf0d9ac078167 · Cited by 1
Nolt, G. L., MacLean, S. M., Golden, L. R., Thorpe, S. P., Stephens, I. O., Funnell, J. L., Brock, C. R., Lucido, C. C., Smith, L., Hernandez, G., et al. (2027) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2026.08.005
Strickland, M. R., & Holtzman, D. M. (2026) · Molecular Neurodegeneration · doi:10.1186/s13024-026-00970-0
“Many reviews have characterized ApoE and its role in homeostasis and impact on AD and AD pathology [1, 3, 4, 7].”
Self-citationMicroglial involvement in brain physiopathology: in vitro studies using rat primary cultures
Mengoni, I. (2014) · AMS Dottorato Institutional Doctoral Theses Repository (University of Bologna) · doi:10.6092/unibo/amsdottorato/6466
Living and Dying with Alzheimer’s Disease: A Case Presentation
Rosa, L. M. D. L. (2015) · American Journal of Nursing Science · doi:10.11648/j.ajns.20150404.20
“Cholesterol metabolism, the growth of nervous system tissue, and the formation of beta-amyloid plaques are noted mechanisms by which receptors could influence the course of Alzheimer’s [6].”
BackgroundInfluentialAlobaidy, A. A. (2013) · International journal of Nutrition Pharmacology Neurological Diseases · doi:10.4103/2231-0738.114831
Abad‐Rodríguez, J. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2012.12.002
Amyloid Beta Accumulation in HIV-1 Infected Brain: The Role of Altered Cholesterol
Chen, X., Lü, H., & Jd, G. (2014)
Dias, B. D. C. (2014) · University of the Witwatersrand, Johannesburg Institutional Repository on DSpace (University of the Witwatersrand, Johannesburg)
Apolipoprotein E and Mitochondria-associated Endoplasmic Reticulum Dysfunction
Tambini, M. D. (2016)
Regulation of apolipoprotein E secretion, lipidation and recycling in the central nervous system
Fan, J. (2014) · cIRcle (University of British Columbia) · doi:10.14288/1.0166830
“Many members of the LDL receptor family are expressed in the CNS (reviewed in Holtzman et al. (2012)).”
BackgroundAlzheimer’s Disease Therapeutics Targeting Apolipoprotein E
Liao, F., & Holtzman, D. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00010-1
Self-citation
Metadata
- Authors
- Holtzman, D. M., Herz, J., & Bu, G.
- Affiliations
- Washington University in St. Louis (US)
- The University of Texas at Dallas (US)
- Mayo Clinic in Florida (US)
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2012-01-10
- Volume
- 2
- Issue
- 3
- Pages
- a006312-a006312
- ISSN
- 2157-1422 (ISSN-L)
- PMC
- PMC3282491
- OpenAlex
- W2143955562
- Cited by
- 782
- References
- 227
- Citations by year
- 2026: 39 · 2025: 45 · 2024: 39 · 2023: 51 · 2022: 76 · 2021: 79 · 2020: 67 · 2019: 66 · 2018: 51 · 2017: 51 · 2016: 60 · 2015: 42 · 2014: 59 · 2013: 41 · 2012: 14
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cold Spring Harbor Perspectives in Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Rare & Special e-Zone (The Hong Kong University of Science and Technology) (submittedVersion)
- Funders
- National Institute on Aging (P01AG030128, R01AG027924, R01AG031784, R01AG035355)
- National Heart, Lung, and Blood Institute (R37HL063762)
- National Institute of Neurological Disorders and Stroke (R37NS034467, P01NS074969)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- apolipoprotein E, APOE isoforms, Alzheimer's disease, APOE ε4, APOE2, apoE receptors, low-density lipoprotein receptor family, ApoER2, VLDLR, LRP1, amyloid-beta, amyloid-beta aggregation, amyloid-beta clearance, lipid modification, synaptic plasticity, neuroinflammation, lipid transport, genetic risk factors, treatment options
- MeSH terms
- Alzheimer Disease, Animals, Apolipoproteins E, Brain, Carrier Proteins, Humans, Neuronal Plasticity, Phosphorylation, Amyloid beta-Peptides, Polymorphism, Single Nucleotide, Protein Transport, Low Density Lipoprotein Receptor-Related Protein-1, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.